Signal Desk · Markets

Glenmark shares rise after US arm launches generic cancer drug

2026-11-16 · 1 source · CNBC TV18 Market

In short

Glenmark Pharmaceuticals shares rose after its US arm launched generic Axitinib Tablets. The drug is an authorized version of Pfizer’s cancer medicine INLYTA, and the launch followed regulatory approval.

The move matters because the new product can add to Glenmark’s US business and caught traders’ attention.

What the reporting says

Glenmark Pharmaceuticals’ shares rose after its US arm launched generic Axitinib Tablets, an authorized version of Pfizer’s cancer drug INLYTA. The launch followed regulatory approval.

Why it matters

Glenmark Pharmaceuticals’ stock moved higher after its US arm launched generic Axitinib Tablets, described as an authorized version of Pfizer’s INLYTA.

Touches: Glenmark Pharmaceuticals, Pfizer, Companies, Healthcare, Markets

Sources